A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

Exclusion Criteria

• •Clinically significant abnormalities other than a history of chronic HBV infection;
• •Concomitant clinically significant other liver diseases;
• •Any serious infection other than chronic hepatitis B infection requiring intravenous anti-infective therapy within 1 month prior to screening;
• •HCV RNA positive, Human immunodeficiency virus (HIV) positive, syphilis positive;
• •Significant liver fibrosis or cirrhosis at screening, or a liver stiffness value (LSM) \> 9.0 kPa;
• •Previous/current manifestations of hepatic decompensation;
• •Diagnosis or suspicion of hepatocellular carcinoma, or alpha-fetoprotein concentration (AFP) ≥ 20 ng/mL at screening;
• •Obviously abnormal laboratory test results;
• •History of vasculitis or presence of signs, symptoms, or laboratory tests of underlying vasculitis, and previous/current other diseases that may be related to vasculitic conditions;
• •QT interval corrected for heart rate (Fridericia method) abnormal;
• •History of extrahepatic disease possibly related to HBV immune status;
• •Participants with a history of malignancy within the past 5 years or who are being evaluated for a possible malignancy;
• •Serious mental illness or history of serious mental illness prior to screening;
• •Suspected history of allergy to any component of the study drug, or allergic constitution;
• •Major trauma or major surgery within 3 months prior to screening, or planned surgery during the study;
• •Those who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study;
• •Current use or use of any immunosuppressive medication within 3 months prior to screening, with the exception of short courses (≤ 2 weeks) or use of topical/inhaled steroids;Those who have used immunomodulators and cytotoxic drugs within 6 months prior to the first dose;Or a history of vaccination within 6 months prior to screening or a live vaccination plan during the trial;
• •Participants requiring regular long-term administration of anticoagulants or antiplatelet drugs;
• •Thyroid dysfunction;
• •Patients with uncontrolled epilepsy and other progressive neurological disorders;
• •Received any antisense oligonucleotides (ASO) or small molecule interfering ribonucleic acid (siRNA) drug;
• •Any other circumstance or condition that, in the opinion of the investigator, the participants are inappropriate for participation in the study.